Skip to main content
. 2021 Mar 5;10(4):286–290. doi: 10.1002/psp4.12597

FIGURE 1.

FIGURE 1

Priority areas for the model‐informed drug development (MIDD) pilot program. As described in the Federal Register Notice, 1 the initial MIDD priority areas include dose selection or estimation, clinical trial simulation, and predictive or mechanistic safety evaluation